Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
暂无分享,去创建一个
Stefan Knapp | Panagis Filippakopoulos | Jenny Bain | P. Cohen | S. Knapp | A. Bullock | J. Bain | M. Prudhomme | P. Filippakopoulos | Philip Cohen | Michelle Prudhomme | Fabrice Anizon | Pascale Moreau | Rufine Akué-Gédu | Emilie Rossignol | Stéphane Azzaro | Alex N. Bullock | Emilie Rossignol | P. Moreau | F. Anizon | Rufine Akué-Gédu | S. Azzaro
[1] Wim Quint,et al. Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region , 1984, Cell.
[2] P. Koskinen,et al. Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site , 2004, FEBS letters.
[3] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[4] P. Cohen,et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.
[5] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[6] Jay Painter,et al. Electronic Reprint Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion , 2005 .
[7] M. Nawijn,et al. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. , 2006, Cancer research.
[8] J. Rokach,et al. Regioselective synthesis of acylpyrroles , 1983 .
[9] A. Berns,et al. Proviral tagging in E mu‐myc transgenic mice lacking the Pim‐1 proto‐oncogene leads to compensatory activation of Pim‐2. , 1995, The EMBO journal.
[10] B. Werneburg,et al. Pim kinase substrate identification and specificity. , 2006, Journal of biochemistry.
[11] S. Knapp,et al. Ruthenium half-sandwich complexes bound to protein kinase Pim-1. , 2006, Angewandte Chemie.
[12] G. Bemis,et al. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase. , 2009, Bioorganic & medicinal chemistry letters.
[13] Randy J Read,et al. Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Translation Functions Biological Crystallography Likelihood-enhanced Fast Translation Functions , 2022 .
[14] S. Knapp,et al. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. , 2007, Cancer research.
[15] O. Silvennoinen,et al. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. , 2004, Blood.
[16] A. Kraft,et al. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. , 2009, Journal of medicinal chemistry.
[17] K. Tsuneyama,et al. Aberrant Pim-3 expression is involved in gastric adenoma–adenocarcinoma sequence and cancer progression , 2008, Journal of Cancer Research and Clinical Oncology.
[18] M. Salto‐Tellez,et al. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. , 2008, European journal of cancer.
[19] Hiroshi Ishikura,et al. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. , 2006, Cancer research.
[20] P. Hammerman,et al. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. , 2005, Blood.
[21] F. Giles. A Pim kinase inhibitor, please , 2005 .
[22] E. Papadimitriou,et al. Pyrrolo[2,3-a]carbazoles as potential cyclin dependent kinase 1 (CDK1) Inhibitors. Synthesis, biological evaluation, and binding mode through docking simulations. , 2008, Journal of medicinal chemistry.
[23] K. Tsuneyama,et al. Essential contribution of Ets‐1 to constitutive Pim‐3 expression in human pancreatic cancer cells , 2009, Cancer science.
[24] M. Lilly,et al. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. , 2007, Bioorganic & medicinal chemistry.
[25] S. Diamond,et al. Toward the development of a potent and selective organoruthenium mammalian sterile 20 kinase inhibitor. , 2009, Journal of medicinal chemistry.
[26] P. Cohen,et al. The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.
[27] G. E. Atilla‐Gokcumen,et al. Exploring Chemical Space with Organometallics: Ruthenium Complexes as Protein Kinase Inhibitors , 2007 .
[28] T. Tsuruo,et al. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. , 2008, Cancer research.
[29] L. Chodosh,et al. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. , 2003, Genes & development.
[30] Jos Jonkers,et al. Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors , 2004, Molecular and Cellular Biology.
[31] M. J. Weiss,et al. Synthesis of indoles from 4-oxo-4,5,6,7-tetrahydroindoles. II. Introduction of substituents into the 4 and 5 positions , 1971 .
[32] Jun Li,et al. Structural Basis of Constitutive Activity and a Unique Nucleotide Binding Mode of Human Pim-1 Kinase* , 2005, Journal of Biological Chemistry.
[33] C. Homon,et al. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. , 2009, Journal of medicinal chemistry.
[34] M. Pudlo,et al. First Suzuki-Miyaura type cross-coupling of ortho-azidobromobenzene with arylboronic acids and its application to the synthesis of fused aromatic indole-heterocycles , 2007 .
[35] M. Lilly,et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase , 2007, Molecular Cancer Therapeutics.
[36] Yoshiaki Ito,et al. Pim-1 kinase phosphorylates RUNX family transcription factors and enhances their activity , 2006, BMC Cell Biology.
[37] Eric F. Johnson,et al. Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling. , 2008, Bioorganic & medicinal chemistry letters.
[38] M. Fousteris,et al. Pyrrolocarbazole analogs of aromatic skeleton of indolocarbazole natural products , 2004 .
[39] K. Tsuneyama,et al. Proto‐oncogene, Pim‐3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad‐mediated apoptosis , 2007, Cancer science.
[40] T. Pilati,et al. Synthesis of [a]annulated carbazoles from indol-2,3-dione , 1993 .
[41] T. Möröy,et al. The serine/threonine kinase Pim-1. , 2005, The international journal of biochemistry & cell biology.
[42] R. Reeves,et al. Recombinant human pim-1 protein exhibits serine/threonine kinase activity. , 1991, The Journal of biological chemistry.
[43] T. Möröy,et al. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. , 2006, The international journal of biochemistry & cell biology.
[44] A. Berns,et al. The pim‐1 oncogene encodes two related protein‐serine/threonine kinases by alternative initiation at AUG and CUG. , 1991, The EMBO journal.
[45] S. Knapp,et al. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. , 2005, Journal of medicinal chemistry.